| Literature DB >> 9784102 |
Q Zeng1, Y Kwok, S M Kerwin, G Mangold, L H Hurley.
Abstract
A new class of pyridobenzophenoxazine compounds has been developed as topoisomerase II inhibitors for anticancer chemotherapy. These compounds were designed based on a proposed model of a quinobenzoxazine self-assembly complex on DNA. They showed excellent inhibitory effects on several tumor cell lines with nanomolar IC50 values. Their cytotoxic potency correlates with their ability to unwind DNA and inhibit topoisomerase II.Entities:
Mesh：
Substances：
Year: 1998 PMID： 9784102 DOI： 10.1021/jm980265c
Source DB: PubMed Journal: J Med Chem ISSN： 0022-2623 Impact factor: 7.446